Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas.
Yoshida N, Tsuzuki S, Karube K, Takahara T, Suguro M, Miyoshi H, Nishikori M, Shimoyama M, Tsukasaki K, Ohshima K, Seto M. Yoshida N, et al. Among authors: tsukasaki k. Cancer Sci. 2015 Oct;106(10):1455-62. doi: 10.1111/cas.12742. Epub 2015 Aug 13. Cancer Sci. 2015. PMID: 26176172 Free PMC article.
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R. Yamamoto K, et al. Among authors: tsukasaki k. J Clin Oncol. 2010 Mar 20;28(9):1591-8. doi: 10.1200/JCO.2009.25.3575. Epub 2010 Feb 22. J Clin Oncol. 2010. PMID: 20177026 Clinical Trial.
Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M. Watanabe T, et al. Among authors: tsukasaki k. Leuk Lymphoma. 2010 May;51(5):813-21. doi: 10.3109/10428191003721359. Leuk Lymphoma. 2010. PMID: 20367565
Lymphoma study group of JCOG.
Tsukasaki K, Tobinai K, Hotta T, Shimoyama M. Tsukasaki K, et al. Jpn J Clin Oncol. 2012 Feb;42(2):85-95. doi: 10.1093/jjco/hyr168. Epub 2011 Dec 6. Jpn J Clin Oncol. 2012. PMID: 22147803 Review.
Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T, Tobinai K, Takeyama K, Shibata T, Hidaka M, Kurosawa M, Kasai M, Chou T, Fukushima N, Mukai K, Tsukasaki K, Shimoyama M; Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG), Tokyo, Japan. Azuma T, et al. Among authors: tsukasaki k. Jpn J Clin Oncol. 2012 May;42(5):394-404. doi: 10.1093/jjco/hys029. Epub 2012 Mar 15. Jpn J Clin Oncol. 2012. PMID: 22422899 Clinical Trial.
Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y; Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG). Ogura M, et al. Among authors: tsukasaki k. Leuk Lymphoma. 2013 Jan;54(1):46-52. doi: 10.3109/10428194.2012.705000. Epub 2012 Aug 21. Leuk Lymphoma. 2013. PMID: 22712838 Clinical Trial.
251 results